Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
The new hospital is expected to open by March'24
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
For the first time in India – fast, precise and efficient calibration of multi-channel micropipettes
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Subscribe To Our Newsletter & Stay Updated
